The past, present, and future status of multimodality treatment for resectable/borderline resectable pancreatic ductal adenocarcinoma

A multimodal approach to treating pancreatic ductal adenocarcinoma (PDAC) is now widely accepted. Improvements in radiological assessment have enabled us to define resectability in detail. Multimodality treatment is essential for patients, especially for those with PDAC in the borderline resectable...

Descripción completa

Detalles Bibliográficos
Autores principales: Sakaguchi, Tatsuma, Satoi, Sohei, Yamamoto, Tomohisa, Yamaki, So, Sekimoto, Mitsugu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Singapore 2020
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7098925/
https://www.ncbi.nlm.nih.gov/pubmed/31993761
http://dx.doi.org/10.1007/s00595-020-01963-2
_version_ 1783511249046208512
author Sakaguchi, Tatsuma
Satoi, Sohei
Yamamoto, Tomohisa
Yamaki, So
Sekimoto, Mitsugu
author_facet Sakaguchi, Tatsuma
Satoi, Sohei
Yamamoto, Tomohisa
Yamaki, So
Sekimoto, Mitsugu
author_sort Sakaguchi, Tatsuma
collection PubMed
description A multimodal approach to treating pancreatic ductal adenocarcinoma (PDAC) is now widely accepted. Improvements in radiological assessment have enabled us to define resectability in detail. Multimodality treatment is essential for patients, especially for those with PDAC in the borderline resectable (BR) stage. Even for disease in a resectable (R) stage, adjuvant and neoadjuvant therapies have demonstrated beneficial outcomes in several trials and analyses. Thus, there is growing interest in optimization of the perioperative therapeutic strategy. We discuss the transition of resectability criteria and the global standard of adjuvant and neoadjuvant treatments for patients with R/BR-PDAC.
format Online
Article
Text
id pubmed-7098925
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Springer Singapore
record_format MEDLINE/PubMed
spelling pubmed-70989252020-03-27 The past, present, and future status of multimodality treatment for resectable/borderline resectable pancreatic ductal adenocarcinoma Sakaguchi, Tatsuma Satoi, Sohei Yamamoto, Tomohisa Yamaki, So Sekimoto, Mitsugu Surg Today Review Article A multimodal approach to treating pancreatic ductal adenocarcinoma (PDAC) is now widely accepted. Improvements in radiological assessment have enabled us to define resectability in detail. Multimodality treatment is essential for patients, especially for those with PDAC in the borderline resectable (BR) stage. Even for disease in a resectable (R) stage, adjuvant and neoadjuvant therapies have demonstrated beneficial outcomes in several trials and analyses. Thus, there is growing interest in optimization of the perioperative therapeutic strategy. We discuss the transition of resectability criteria and the global standard of adjuvant and neoadjuvant treatments for patients with R/BR-PDAC. Springer Singapore 2020-01-28 2020 /pmc/articles/PMC7098925/ /pubmed/31993761 http://dx.doi.org/10.1007/s00595-020-01963-2 Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
spellingShingle Review Article
Sakaguchi, Tatsuma
Satoi, Sohei
Yamamoto, Tomohisa
Yamaki, So
Sekimoto, Mitsugu
The past, present, and future status of multimodality treatment for resectable/borderline resectable pancreatic ductal adenocarcinoma
title The past, present, and future status of multimodality treatment for resectable/borderline resectable pancreatic ductal adenocarcinoma
title_full The past, present, and future status of multimodality treatment for resectable/borderline resectable pancreatic ductal adenocarcinoma
title_fullStr The past, present, and future status of multimodality treatment for resectable/borderline resectable pancreatic ductal adenocarcinoma
title_full_unstemmed The past, present, and future status of multimodality treatment for resectable/borderline resectable pancreatic ductal adenocarcinoma
title_short The past, present, and future status of multimodality treatment for resectable/borderline resectable pancreatic ductal adenocarcinoma
title_sort past, present, and future status of multimodality treatment for resectable/borderline resectable pancreatic ductal adenocarcinoma
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7098925/
https://www.ncbi.nlm.nih.gov/pubmed/31993761
http://dx.doi.org/10.1007/s00595-020-01963-2
work_keys_str_mv AT sakaguchitatsuma thepastpresentandfuturestatusofmultimodalitytreatmentforresectableborderlineresectablepancreaticductaladenocarcinoma
AT satoisohei thepastpresentandfuturestatusofmultimodalitytreatmentforresectableborderlineresectablepancreaticductaladenocarcinoma
AT yamamototomohisa thepastpresentandfuturestatusofmultimodalitytreatmentforresectableborderlineresectablepancreaticductaladenocarcinoma
AT yamakiso thepastpresentandfuturestatusofmultimodalitytreatmentforresectableborderlineresectablepancreaticductaladenocarcinoma
AT sekimotomitsugu thepastpresentandfuturestatusofmultimodalitytreatmentforresectableborderlineresectablepancreaticductaladenocarcinoma
AT sakaguchitatsuma pastpresentandfuturestatusofmultimodalitytreatmentforresectableborderlineresectablepancreaticductaladenocarcinoma
AT satoisohei pastpresentandfuturestatusofmultimodalitytreatmentforresectableborderlineresectablepancreaticductaladenocarcinoma
AT yamamototomohisa pastpresentandfuturestatusofmultimodalitytreatmentforresectableborderlineresectablepancreaticductaladenocarcinoma
AT yamakiso pastpresentandfuturestatusofmultimodalitytreatmentforresectableborderlineresectablepancreaticductaladenocarcinoma
AT sekimotomitsugu pastpresentandfuturestatusofmultimodalitytreatmentforresectableborderlineresectablepancreaticductaladenocarcinoma

Ejemplares similares